Corrigendum to: Mechanism of HSP90 Inhibitor in the Treatment of DSS-induced Colitis in Mice by Inhibiting MAPK Pathway and Synergistic Effect of Compound Sophorae Decoction
- PMID: 38975683
- DOI: 10.2174/138161283017240501215827
Corrigendum to: Mechanism of HSP90 Inhibitor in the Treatment of DSS-induced Colitis in Mice by Inhibiting MAPK Pathway and Synergistic Effect of Compound Sophorae Decoction
Abstract
A typographical error appeared in the title of the article "Mechanism of HSP90 Inhibitor in the Treatment of DSS-induced Colitis in Mice by Inhibiting MAPK Pathway and Synergistic Effect of Compound Sophora Decoction", published in Current Pharmaceutical Design, 2022; 28(42): 3456-3468 [1]. Details of the error and a correction are provided below. Original: Mechanism of HSP90 Inhibitor in the Treatment of DSS-induced Colitis in Mice by Inhibiting MAPK Pathway and Synergistic Effect of Compound Sophora Decoction Corrected: Mechanism of HSP90 Inhibitor in the Treatment of DSS-induced Colitis in Mice by Inhibiting MAPK Pathway and Synergistic Effect of Compound Sophorae Decoction We regret the error and apologize to readers. The original article can be found online at: https://www.eurekaselect.com/article/127740.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Erratum for
-
Mechanism of HSP90 Inhibitor in the Treatment of DSS-induced Colitis in Mice by Inhibiting MAPK Pathway and Synergistic Effect of Compound Sophorae Decoction.Curr Pharm Des. 2022;28(42):3456-3468. doi: 10.2174/1381612829666221122113929. Curr Pharm Des. 2022. PMID: 36415092
References
-
- Yuyi Y.; Hui W.; Bo S.; Mechanism of HSP90 inhibitor in the treatment of DSS-induced colitis in mice by inhibiting MAPK pathway and synergistic effect of compound sophora decoction. Curr Pharm Des 2022,28(42),3456-3468 - DOI
Publication types
LinkOut - more resources
Full Text Sources